People who got the shingles vaccine had a lower rate of dementia, researchers found

A vaccine given to protect older adults from a painful rash has become one of the most closely watched leads in dementia research. Several studies, including one built around an unusual quirk of a national vaccination program, have found that people who received a shingles shot went on to develop dementia at a lower rate than those who did not. The results have strengthened a broader theory that certain viral infections may contribute to cognitive decline, and that guarding against them might offer some protection.

The findings are unusually persuasive for observational research, because one of the key studies came close to the conditions of a real experiment. Even so, the scientists behind the work are careful to describe an association and a plausible mechanism rather than a proven, direct effect on the brain.

The natural experiment in Wales

The most influential evidence emerged from a vaccine rollout in Wales that inadvertently created a natural experiment. When the country’s health service began offering the shingles vaccine, it used a strict eligibility rule based on date of birth, so that people born just before a cutoff were ineligible while those born just after qualified. That arrangement produced two groups that were nearly identical in every respect except their access to the shot, allowing researchers to compare them with unusual confidence.

Analyzing those records, the team reported in the journal Nature that people who received the vaccine were about 20% less likely to develop dementia over the following seven years than those who narrowly missed eligibility. Because the two groups were separated only by a birth-date threshold rather than by choices or health status, the comparison sidesteps much of the confounding that usually clouds this kind of study.

Why the birth-date cutoff matters

In most vaccine studies, the people who get vaccinated differ from those who do not in ways that are hard to measure, such as being more health-conscious, wealthier or more engaged with medical care, any of which could independently affect dementia risk. The Welsh design largely neutralizes that problem. Whether someone was born a few weeks earlier or later is effectively random with respect to their future health, so a difference in dementia rates between the groups is difficult to explain away as a byproduct of who chose to be vaccinated.

Researchers at Stanford who led the analysis described the result as stronger evidence than a typical correlation, precisely because of that quasi-experimental structure. The study focused on the older live-attenuated shingles vaccine, since the newer version had not yet been in use long enough during the follow-up window.

How a virus might raise dementia risk

The biological rationale centers on the varicella-zoster virus, which causes chickenpox and then lingers dormant in the nervous system for life, sometimes reactivating decades later as shingles. Reactivation can inflame nerves and blood vessels, and some scientists suspect that repeated viral flare-ups, or the inflammation they trigger, could contribute to the processes that damage the aging brain. A vaccine that prevents reactivation might, in turn, reduce that cumulative insult.

There is also a possibility that the protection is not entirely specific to the virus. Some researchers have raised the idea that vaccines can produce broader effects on the immune system that influence dementia risk, which would complicate any simple story about blocking one particular infection. Sorting out which mechanism is at work is an active area of investigation.

What the findings do and do not show

Supporting studies have pointed in the same direction. Research using data from Australia, where a similar age-based eligibility rule applied, found comparable reductions in dementia risk among the vaccinated, and later work has examined how the timing of vaccination relates to the course of the disease. The convergence of independent datasets is part of what makes the signal credible.

Still, the evidence stops short of proving that shingles vaccination prevents dementia. Even the strongest of these studies observe what happened to large groups rather than randomly assigning shots and outcomes, and none establishes with certainty that the vaccine acts directly on the disease process. The practical implication is modest but real: shingles vaccination is already recommended for older adults to prevent a genuinely debilitating illness, and the emerging dementia research adds another reason to consider it, without yet justifying claims that the shot is a proven safeguard for the brain.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview